Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.37 |
| ▸ | CA1 | P00915 | 9/20 | 0.37 |
| ▸ | MMP1 | P03956 | 5/20 | 0.37 |
| ▸ | MMP2 | P08253 | 5/20 | 0.37 |
| ▸ | MMP9 | P14780 | 5/20 | 0.37 |
| ▸ | MMP8 | P22894 | 5/20 | 0.37 |
| ▸ | MMP13 | P45452 | 5/20 | 0.37 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461257 | 0.82 | CA2 (0.40) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL575405 | 0.82 | CA2 (0.40) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL979982 | 0.80 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL576166 | 0.80 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL18807459 | 0.80 | CA2 (0.39) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL575657 | 0.80 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL25394926 | 0.78 | CA2 (0.38) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL975664 | 0.78 | CA2 (0.38) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL30067119 | 0.78 | CA2 (0.38) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL15864676 | 0.78 | CA2 (0.45) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4581035-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20240415840-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2024-12-19 | — | — | US | disclosed |
| US-20240140938-A1 | PREPARATION OF TETRAHYDROINDAZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240116945-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024049931-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4267135-A1 | PREPARATION OF TETRAHYDROINDAZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116783187-A | Preparation of tetrahydroindazole derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022140169-A1 | PREPARATION OF TETRAHYDROINDAZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415840-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CCNI, CDK1 | CA2 2665/4885CA1 3747/4885MMP1 3978/4885 |
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | CA2 3659/4885CA1 3797/4885MMP1 858/4885 |
| US-20240140938-A1 | PREPARATION OF TETRAHYDROINDAZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | CA2 3508/4885CA1 3776/4885MMP1 762/4885 |
| US-20240116945-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | TOP1, TOP2A, TOP2B | CA2 2847/4885CA1 2166/4885MMP1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.